Vitiligo: Auto‐immunity and immune responses
2005; Wiley; Volume: 45; Issue: 5 Linguagem: Italiano
10.1111/j.1365-4632.2005.02651.x
ISSN1365-4632
AutoresVirendra Sehgal, Govind Srivastava,
Tópico(s)Atherosclerosis and Cardiovascular Diseases
ResumoInternational Journal of DermatologyVolume 45, Issue 5 p. 583-590 Vitiligo: Auto-immunity and immune responses Virendra N. Sehgal MD, Virendra N. Sehgal MD From the Dermato-Venereology (Skin/VD) Center, Sehgal Nursing Home, Panchwati, Azadpur, Delhi, and the Skin Institute and School of Dermatology, Greater Kailash, New Delhi, IndiaSearch for more papers by this authorGovind Srivastava MD, Govind Srivastava MD From the Dermato-Venereology (Skin/VD) Center, Sehgal Nursing Home, Panchwati, Azadpur, Delhi, and the Skin Institute and School of Dermatology, Greater Kailash, New Delhi, IndiaSearch for more papers by this author Virendra N. Sehgal MD, Virendra N. Sehgal MD From the Dermato-Venereology (Skin/VD) Center, Sehgal Nursing Home, Panchwati, Azadpur, Delhi, and the Skin Institute and School of Dermatology, Greater Kailash, New Delhi, IndiaSearch for more papers by this authorGovind Srivastava MD, Govind Srivastava MD From the Dermato-Venereology (Skin/VD) Center, Sehgal Nursing Home, Panchwati, Azadpur, Delhi, and the Skin Institute and School of Dermatology, Greater Kailash, New Delhi, IndiaSearch for more papers by this author First published: 20 July 2005 https://doi.org/10.1111/j.1365-4632.2005.02651.xCitations: 23 Virendra N. Sehgal, MD, FNASC, FAMS, FRAS (Lond.) A/6, Panchwati Delhi – 110 033 India E-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Lerner A. Vitiligo. J Invest Dermatol 1959; 32: 285–310. 2 Howitz J, Brodthage H, Schwartz M, et al. Prevalence of vitiligo- epidemiological survey on the isle of Bornholm, Denmark. Arch Dermatol 1977; 113: 47–52. 3 Kovacs SD. Vitiligo. J Am Acad Dermatol 1998; 38: 647–666. 4 Handa S, Dogra S. Epidemiology of childhood vitiligo – a study of 625 patients from North-India. Pediator Dermatol 2003; 20: 207–210. 5 Herane MI. Vitiligo and leukoderma in children. Clin Dermatol 2003; 21: 283–295. 6 Ortonne JP, Mosher DB, Fitzpatrick TB. Vitiligo and the hypomelanosis of hair and skin. New York: Plenum Medical Book Company, 1983: 172–176. 7 Penkus H. Vitiligo – what is it? J Invest Dermatol 1959; 32: 281–284. 8 Srivastava G. Vitiligo – Introduction. Asian Clinic Dermatol 1994; 1: 1–5. 9 Barnes L. Vitiligo and Vogt–Koyanagi – Harada syndrome. Dermatol Clin 1988; 6: 229–239. 10 Njoo MD, Weskrhof W. Vitiligo, pathogenesis and treatment. Am J Clin Dermatol 2001; 2: 167–168. 11 Sehgal VN, Dube B. Secretary state in vitiligo. Dermatologica 1969; 138: 89–92. 12 Bhawan J, Bhutani LK. Keratinocyte damage in vitiligo. J Cutan Pathol 1983; 10: 207–212. 13 Iynger B, Misra RS. Neural differentiation of melanocytes in vitiliginous skin. Acta Anat (Basel) 1988; 133: 62–65. 14 Lee Poole LC, Das PK, Wijngard RM, et al. Review of the etio-pathologic mechanism of vitiligo – a convergence theory. Exp Dermatol 1993; 2: 145–158. 15 Rawles ME. Origin of melanophore and their role in development of color pattern in vertebrates. Physiol Rev 1948; 28: 382–408. 16 Lerner AB, Norland JJ. The loss of pigment in skin, hair and eyes. J Dermatol (Tokyo) 1978; 5: 1–8. 17 Tababa OA, Owolabi MO, Osotimehin BO. Auto immune diseases in a Nigerian woman. West Afr J Med 2003; 22: 361–363. 18 Norland JJ. The significance of de-pigmentation. Pigm cell Res 1992; 2: 237–241. 19 Smyth JR Jr, McNeil M. Alopecia areata and universalis in the Smyth chicken mode for spontaneous vitiligo. J Invest Dermatol Sym Proe 1999; 4: 211–215. 20 Belterle C, Caretto A, DeZio A, et al. Incidence and significance specific autoimmune disorders in patients with vitiligo. Dermatologica 1985; 171: 419–423. 21 Belterle C, Deeprete G, Preserico A, et al. Auto-antibodies in vitiligo. Arch Dermatol 1976; 112: 1328–1330. 22 Burns-Cox C, Pearson J. Addison's diseases, vitiligo and multiple auto-antibodies. Postgr Med J 1972; 48: 115–117. 23 Fields J, Fragola L, Hadley T. Hypo-parathyroidism, candidiasis, alopecia and vitiligo. Arch Dermatol 1971; 103: 687–690. 24 Fisher M, Fitzpatrick T. Candidiasis, vitiligo, additions disease and hypoparathyroidism. Arch Dermatol 1970; 102: 110–112. 25 Koga M, Tango T. Clinical features of type A and type B vitiligo. Br J Dermatol 1988; 118: 223–228. 26 Forcier R, McJntyre O, Frey W. Auto-immunity and multiple endocrine abnormalities. Arch Inter Med 1972; 129: 638–641. 27 Cunliffe W, Hall R, Newell J, et al. Vitiligo, thyroid disease and auto-immunity. Br J Dermatol 1968; 80: 135–139. 28 Shellreuter KU, Lenke R, Brandt O, et al. Vitiligo and the disease – co-existence or true association? Dermatology 1994; 188: 269–275. 29 Koshiyama H, Ito M, Yoshinami N, et al. Two cases of asymptomatic adrenocortical insufficiency with auto-immune thyroid disease. Endoer J 1994; 41: 373–378. 30 Allisan J, Curtis A. Vitiligo and pernicious anaemia. Arch Dermatol 1955; 72: 407–409. 31 Grunnel I, Hawitz J. Vitiligo and pernicious anaemia. Arch Dermatol 1970; 101: 82–85. 32 Dawber R. Integumentary association of pernicious anaemia. Br J Dermatol 1969; 82: 221–222. 33 Harrakahi MSE. Pernicious anaemia in Arabs. Blood Cells Mol Dis 1996; 22: 98–103. 34 Dawber R. Vitiligo in mature onset diabetes mellitus. Br J Dermatol 1968; 80: 275–278. 35 Husebye ES, Gebre-Melhin G, Tuomi T, et al. Auto-antibodies against aromatic amino and decarboxylase auto–immune polyendocrine syndrome type I. J Clin Endocrinal Metabol 1997; 82: 147–150. 36 Sharma VK, Dawn G, Kumar B. Profile of alopecia areata in Northern India. Int J Dermatol 1996; 35: 22–27. 37 Sharma VK, Kumar B, Dawn G. A clinical study of childhood alopecia areata in Chandigarh, India. Pediator Dermatol 1996; 13: 372–377. 38 Cecchi R, Giomi A, Tua F, et al. PRP, lichen planus, alopecia universalis and vitiligo in a patient of chronic viral hepatitis – C. Dermatology, 1994; 188: 239–240. 39 Dunlop D. Eighty six cases of Addison's disease. Br Med J 1963; 2: 887–891. 40 Meecham J, Jones E. Addison's disease and Addisonian anemia. Lan Et 1967; 1: 535–538. 41 Bystran J. Serum antibodies in vitiligo patients. Clin Dermatol 1989; 7: 136–145. 42 Norlund JJ, Majundar PP. Recent investigation and vitiligo vulgaris. Dermatol Clin 1997; 15: 69–78. 43 Okada T, Sakamoto T, Ishibaslin T, et al. Vitiligo in Vogt-Kyanagi Hrada disease. Gracres Arch Clin Exp Ophthalmol 1996; 234: 359–363. 44 Okamoto T, Irie RF, Fujii S, et al. Anti-tyrosinase releted protein-2 immune response in vitiligo patients and helanoma patients recurring active specific immuno therapy. J Invest Dermatol 1998; 111: 1034–1039. 45 Merimsky O, Shoefeld Y, Fisherman P. The clinical significance antity-rosinase antibodies in melanoma and related hypo-pigmentary disorders. Clin Rev Allergis Dimmunol 1998; 16: 227–236. 46 Hann SK, Shin HK, Park SH, et al. Detection of antibodies to melanocytes in vitiligo by western immunoblotting. Yonsel Med J 1996; 37: 365–370. 47 Mandry RC, Qrtiz LJ, Lugo-somolinos A, et al. Organ-specific auto-antibodies in vitiligo patients and their relatives. Int J Dermatol 1996; 35: 18–21. 48 Mayunder P, Norlund J, Nath S. Pattern of familial aggregation of vitiligo. Arch Dermatol 1993; 129: 994–998. 49 Venkatraman MN, White AG, Leeny WA, et al. HLA antigens in Omani patients with vitiligo. Clin Exp Dermatol 1995; 20: 35–37. 50 AL-fouzan A, Al-Arbash M, Fonad F, et al. Study of HLA class I/II and T-lymphocyte subset in K uwaiti vitiligo patients. Eur J Immunogint 1995; 22: 209–213. 51 Hafez M, Sharf L, Abdel-Nabi S. The genetics of vitiligo. Acta Derm Venereal (stockh) 1983; 63: 249–251. 52 Nath SK, Majumdar PP, Norland JJ. Genetic epidemiology of vitiligo-multilocus recessivity crossvali-dated. Am J Hum Genet 1994; 55: 981–990. 53 Das S, Majundar P, Chakraborty R, et al. Studies and vitiligo – epidemiological profile in Calcutta, India. Genet Epidemiol 1985; 2: 71–78. 54 Majundar P, Lic DAS. A Genetical model for vitiligo. Am J Human Genetic 1988; 43: 19–125. 55 Merelender J, Rywlen J. Hereditary of acquired vitiligo. Acta Derm Venereol (stock h) 1940; 21: 583–585. 56 Sehgal VN. A clinical evaluation of 202 cases of vitiligo. Cutis 1974; 14: 439–445. 57 Behl PN. Vitiligo. In: PN Behl, A Aggarwal, G Srivastava, eds. Practice of Dermatology, 9th edn. New Delhi, India: CBS Publishers, 2003: 235–239. 58 Siemens HW. Die Zuvillings pathologie der vitiligo. Acta Genet Med Gemelol (Roman) 1953; 2: 118–124. 59 Mohar J. Vitiligo in a pair of mono-ovular twins. Acta Genet Stat Med 1951; 2: 252–255. 60 Jin SY, Park MH, Li GZ, et al. Association of angiotensin converting enzyme gene I/D polymorphism of vitiligo in Korean population. Pigment Cell Res 2004; 17: 84–86. 61 Spritz RA, Gowan K, Bennett DC, et al. Novel vitiligo susceptibility loci on chromosome 7 (AIS2) and 8 (AIS3) confirmation of SLEVI on chromosome 17, and their roles in an autoimmune diathesis. Am J Hum Genet 2004; 74: 188–191. 62 Lowerstein EJ, Kim KH, Click SA. Turner's syndrome in dermatology. J Am Acad Dermatol 2004; 50: 767–776. 63 Metzker A, Zamir R, Gazit E, et al. Vitiligo and HLA system. Dermatologica 1980; 160: 100–105. 64 Foley L, Lowe N, Misheloff E, et al. Association of HLA- DR4 with vitiligo. J Am Acad Dermatol 1983; 8: 38–40. 65 Dunston G, Halder R. Vitiligo in associated with HLA-DR4 in black patients. Arch Dermatol 1990; 126: 56–60. 66 Poloy Tibor L, Kramer J, et al. HLA-DR1 is associated with vitiligo. Immunol Lett 1991; 27: 59–62. 67 Finico O, Cuccia M, Matinetti M, et al. Age of onset in vitiligo- relationship with HLA-serotypes. Clin Genet 1991; 39: 48–54. 68 Lorini R, Orecchia G, Martinetti M, et al. Auto immunity in vitiligo – relationship with HLA. Gm and Km polymorphisim. Autoimmunity 1992; 11: 255–260. 69 Orecchia G, Perfeti P, Malagoli F, et al. Vitiligo is associated with a significant increase in HLA-A30, CW6 and DQW3 and a decrease in C4AQo in northern Italian patients. Dermatology, 1992; 185: 123–127. 70 Vennekar G, Westerhof W, Devries I, et al. Molecular heterogeneity of C4 and its genes in vitiligo. J Invest Dermatol 1992; 99: 853–858. 71 Buc M, Busova B, Hegyi E, et al. Vitiligo is associated with HLA-A3, and HLA-DW7 in Slovak populations. Folia Biologica, 1996; 42: 23–25. 72 Naughtom GK, Eisinger M, Bystran JC. Detection of antibodies to melanocytes in vitiligo by specific immuno precipitation. J Invest Dermatol 1983; 81: 540–542. 73 Harning R, Cui J, Bystrian JC. Rebtion between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 1991; 97: 1078–1080. 74 Hertz KC, Gaze LA, Kirkpatrick CH, et al. Autoimmune vitiligo – detection of antibodies to melanin producing cell. N Engl J Med 1977; 297: 634–637. 75 Naughton GK, Eisnger M, Bystryn JC. Antibodies to normal human melanocytes in vitiligo. J Exp Med 1983; 158: 246–251. 76 Cui J, Harning R, Hemm M, et al. Identification of pigment cell antigens defined by vitiligo antibodies. J Invest Dermatol 1992; 98: 162–165. 77 Norris DA, Kissinger RM, Naughton GM, et al. Evidence for immunologic mechanisms in human vitiligo. J Invest Dermatol 1988; 90: 783–789. 78 Venneker GT, Puri N, Westerhof W, et al. Membrane co-factor protein (MCP) and decay acceleration factor are grossly reduced in vitiligo lesions. Pigment Cell Res 1992; 5: 1998. 79 Howanitz N, Norland J, Lermer A. Antibodies to melanocytes. Arch Dermatol 1981; 117: 705–708. 80 Norris A, Todd C, Grahant XX, et al. The expression of the C-kit receptor by epidermal melanocytes may be reduced vitiligo. Br J Dermatol 1996; 134: 299–306. 81 Puri N, Moginder M, Ramaih A. Growth defects of melanocytes in culture from vitiligo subjects are spontaneously corrected in vivo in re-pigmented subjects, and can partially corrected by addition of Fibroblast derived growth factor in vitro. Arch Dermatol Res 1989; 281: 178–184. 82 Morris DA, Horikawa T, Morelli JG. Melanocytes destruction and repopulation in vitiligo. Pigments Cell Res 1994; 7: 193–203. 83 Hann SK, Kin HI, Im S, et al. The change of melanocytes cytotoxicity after systemic steroid treatment in vitiligo patients. J Dermatol Sci 1993; 6: 201–205. 84 Sehgal VN, Dube B. ABO groups and vitiligo. J Med Genet 1968; 5: 308–309. 85 Sehgal VN, Dube B. Secretion of blood group specific substances in saliva of vitiligo patients. Br J Dermatol 1976; 79: 704–705. 86 Aronson P, Hashimoto K. Association of IgA anti-melanoma antibodies in the area of vitiligo patients with active disease. J Invest Dermatol 1987; 8: 475–477. 87 Bic C, Suender J, Soltani K, et al. Anti-melanocytes antibodies and vitiligo. J Invest Dermatol 1989; 92: 403–408. 88 Yu J, Kao C, Yu C. Co-existence and relationship of anti-keratinocyte and anti-melanocytes antibodies in patients with non-segmental type vitiligo. J Invest Dermatol 1993; 100: 823–828. 89 Naughton G, Reggiardo D, Bystryn J. Correlation between vitiligo antibodies and extent of de-pigmentation in vitiligo. J Am Acad Dermatol 1986; 15: 978–981. 90 Baharav E, Merimski O, Shoefeld Y, et al. Tyrosinase as an auto-antigen in patients with vitiligo. Clin Exp Immunol 1996; 105: 84–88. 91 Merimsky O, Baharav E, Shoefeld Y, et al. Anti-tyrosinase antibodies in malignant melanoma. Cancer Immunol Dermo Another 1996; 42: 297–302. 92 Hammer H. Lymphocytes transformation test in sympathetic ophthalmitis and the Vogt Koyanagi–Harada syndrome. Br J Optithalm 1971; 55: 850–852. 93 Hammer H. Cellular hypersensitivity to uveal pigment conformed by leucocyte migration test in sympathetic ophthalmitis and Vogt–Koyanagi Harada syndrome. Br J Ophiliam 1974; 59: 773–776. 94 Wojdani A, Grinme P, Loch L, et al. Detection of anti-benzene ring antibodies in patients with vitiligo. J Invest Dermatol 1992; 92: 644–648. 95 Xiap XX, Geoghegan W, Jordan R. Vitiligo antibodies – studies of sub class distribution and complement activation. I Invest Dermatol 1991; 96: 627–631. 96 Dal Pra C, Chen S, Betterle C, et al. Autoantibodies to human tryptophan hydroxylase and aromatic 1-amino acid decarboxylase. Eur J Endocrinol 2004; 150: 313–321. 97 Beisland C, Holsen DS. Vitiligo-an autoimmune side-effect of intravesical bacillus Calmette-Guerin instillation? Scand J Urol Nephrol 2004; 38: 182–183. 98 Horn TD, Abanni A. Analysis of the lymphocytic infiltrate in a case of vitiligo. Am J Histopathol 1997; 19: 400–402. 99 Mozzamica N, Frigerio U, Fwizi AF, et al. T-cell subpopulations in vitiligo – a chronological study. J Am Acad Dermatol 1990; 22: 223–230. 100 Mahmoud F, Abul M, Hairies D, et al. Decreased total numbers of peripheral blood lymphocytes with elevated percentage of CD4+CD45 RO+ and CD4+CD25+ of T helper cells in non-segmental vitiligo. J Dermatol 2002; 29: 68–73. 101 Abdel-Naser MB, Lirding WD. Non-segmental vitiligo – decrease of the CD45RA+ T-cells subset, and evidence for peripheral T-cell activation. Int J Dermatol 1992; 31: 321–326. 102 Sehgal VN, Dube B. Secretary state – a positive prognostic sign in vitiligo. Dermatologica 1969; 139: 168–171. 103 Le Poole JC, Den-Wizngaard RM, Westerhof W, et al. Presence of T-cells and macrophages in inflammatory vitiligo skin parallels melanocytes disappearance. Am J Pathol 1996; 148: 1219–1228. 104 Antony FC, Marsden RA. Vitiligo in association with HIV infection. J Eur Acad Dermatol Venereol 2003; 17: 456–458. 105 Grimes P, Ghoneum M, Stockton T, et al. T-cell profiles in vitiligo. J Am Acad Dermatol, 1986; 14: 196–199. 106 Holder R, Walters C, Jonson B, et al. Aberration of T-lymphocytes and natural killer cell in vitiligo. J Am Acad Dermatol 1986; 14: 733–738. 107 Soubiran P, Benzaken S, Bellet C, et al. Vitiligo T-cell subset unbalance as defined by monoclonal antibodies. Br J Dermatol 1985; 113: 124–127. 108 D'Amelio R, Frati C, Fattorossi A, et al. Peripheral T-cell subset imbalance in patients with vitiligo and their apparently healthy first degree relatives. Ann Allegy 1990; 65: 143–145. 109 Gross A, Tapia FJ, Mosca W, et al. Mononuclear cells sub-populations and infiltratory lymphocytes in erythema dyschromicum perstan and vitiligo. Histoid Histopathol 1987; 2: 277–283. 110 Zaman T, Begum S, Waheed M. In vitro assessment of T-lymphocytes functioning in vitiligo. Acta Derm Venereol (Stockh.) 1992; 72: 2667–2669. 111 Durham-Pierre DG, Walters CS, Halder RM, et al. Natural killer cell and lymphocytic–activated killer cell activity against melanocytes in vitiligo. J Am Acad Dermatol 1995; 33: 26–30. 112 Le Poole IC, Wankowicz-Kalinska A, Van den Wijngaard RM, et al. Autoimmune aspects of de-pigmentation in vitiligo. J Invest Dermtol Symp Proc 2004; 9: 68–72. 113 Kano Y, Shiohara I, Nagashima M. Epidermal Langerhan's cells in various skin diseases (2) Langerhan's cells in vitiligo. J Dermatol (Tokyo) 1984; 11: 103– 110. 114 Westerhof W, Groot I, Krieg SR, et al. Langerhan's cells subpopulation studies with OK T6 and HLA–DR monoclonal antibodies in vitiligo patients treated with oral phenylalanine loading and UVA irradiation. Acta Derm Venereol 1986; 66: 259–262. 115 Palkowski MR, Norlund ML, Rheins LA, et al. Langerhan's cells in hair follicles of the de-pigmentary C57, B1/Ler–vit moue: a model for human skin. Arch Dermatol 1987; 123: 1022–1028. 116 Kao CH, Yu HS. Depletion and repopulation of Langerhan's cells in non-segmental type vitiligo. J Dermatol (Tokyo) 1990; 17: 287–296. 117 Bose SK. Probable mechanism of loss of Markel cells in completely de-pigmented skin of stable vitiligo. J Dermatol (Tokyo) 1994; 21: 725–728. 118 Bose SK. Absence of Markel cells in lesional skin of vitiligo (corrected). Int J Dermaol 1994; 33: 481–483. 119 Bose SK, Ortonne JP. Focal gaps in the basement membrane of involved skin of vitiligo. Are they normal? J Dermatol (Tokyo) 1994; 21: 152–119. 120 Hann SK, Park TK, Lee KG, et al. Epidermal changes in active vitiligo. J Dermatol (Tokyo) 1992; 19: 217–222. 121 Moellmann G. Keratinocyte in vitiligo. J Invest Dermatol, 1992; 99: 665. 122 Philips J, Gawkrodger DJ, Caddy CM, et al. Keratocyte suppresses TRP-1 expression and reduce cell number of co-cultured melanocytes. Pigment Cell Res 2001; 14: 116–125. 123 Hamada T, Sakurane HF, Saito T. Behavior of pigment cells on lesions of the pigmented versus vitiligo. J Dermatol (Tokyo) 1979; 6: 143–152. 124 Lernier AB. Repopulation of pigment cells in patients with vitiligo. Arch Dermatol 1988; 124: 1701–1702. 125 Olssy RE, Liu YY, Medrano EE, et al. Structural aberration of the rough endoplasmic reticulum and melanosome compartmentalization in long term cultures of melanocytes from vitiligo patients. J Invest Dermatol 1991; 97: 395–404. 126 Im S, Hann SK, Park YK, et al. Culture of melanocytes obtained from normal and vitiligo subjects. Yonsei Med J 1992; 33: 344–350. 127 Jee SH, Kuoy F, Wu YC, et al. Growth of human melanocytes from suction blisters of localized vitiligo patients and from foreskins of newborn and adult by modified culture medium. J Formos Med Assoc 1993; 92: 7–14. 128 Le Poole TC, Van den Vigngaard RH, Westerhof W, et al. Presence or absence of melanocytes in vitiligo lesions – an immuno-histo-chemical investigation. J Invst Dermatol 1993; 100: 816–822. 129 Arrunategul A, Arroyo C, Garcia L, et al. Melanocytes reservoir in vitiligo. Int J Dermatol 1994; 33: 484–487. 130 Ozdemir M, Xillar G, Wolf R, et al. Increased basic fibroblast growth factor levels in serum and blister fluid from patients with vitiligo. Acta Derm Venereol 2000; 80: 438–439. 131 Tobin DJ, Swanson NN, Pittelkow MR, et al. Melanocytes are not absent in lesional skin of long duration vitiligo. J Pathol 2000; 191: 407–416. 132 Yu HS. Melanocyte destruction and re-pigmentation in vitiligo: a modal for nerve cell damage and re-growth. J Biomed Sci 2002; 9: 564–573. 133 Gauthier Y, Cario-Andre M, Lepreux S, et al. Melanocyte detachment after skin friction in non-lesional skin of patients with generalized vitiligo. Brit J Dermatol 2003; 148: 95–101. 134 Ortonne JP, Perrot H. Giant melanin granules in vitiligenous achromia with malignant melanoma. Arch Derm Venereol 1978; 58: 475–480. 135 Gokhale B, Mehta LN. Histopathology of the vitiligenous skin. Int J Dermatol 1983; 22: 477–480. 136 Le Poole IC, Das PK. Microscopic changes in vitiligo. Clin Dermatol 1997; 15: 863–873. 137 Montes LF, Abulafia J, Wilborn WH, et al. Value of histopathology in vitiligo. Int J Dermatol 2003; 42: 57–61. 138 Morohashi M, Hashimoto K, Goodman TFJ. Ultra-structural studies of vitiligo, Vogt-Koyanagi–Harada disease, and incontinentia pigmenti achromicans. Arch Dermatol 1977; 113: 755–766. 139 Ishii M, Hamada T. Ultra-structural studies of vitiligo with inflammatory to raised borders. J Dermatol (Tokyo) 1981; 8: 313–322. 140 Galadari E, Mehregan AH, Hashimoto K. Ultra-structural study of vitiligo. Int J Dermatol 1993; 32: 269–271. 141 Panuncio AL, Vignale R. Ultra-structural studies in stable vitiligo. Am J Histopathol 2003; 25: 16–20. 142 Cui J, Chen D, Misfeldt ML, et al. Anti-melanoma antibodies in swine with spontaneously regressing melanoma. Pigment Cell Res 1995; 8: 60–63. 143 Austin L, Boissy R, Jacobson B, et al. The detection of melanocytes antibodies in the Smyth chicken model for vitiligo. Clin Immunol Immunopathol 1992; 64: 112–120. 144 Sreekumar GP, Eft GF, Smyth Jr. 5-azacytidine treatment induces autoimmune vitiligo in parental control strains of the Symth line chicken model for autoimmune vitiligO. Clin Immunol Immunopathol 1996; 81: 136–144. 145 Naughton G, Mahaffey M, Bystryn J. Anti-bodies to surface antigens of pigmented cells in animals with vitiligo. Proc Soc Exp Biol Medical 1986; 181: 423–426. 146 Erf GF, Smyth JR Jr. Alteration in blood leucocyte populations in Smyth line chickens with autoimmune vitiligo. Poultry Sci 1996; 75: 351–356. 147 Erf GF, Trejo-Steal I, Av Smyth JR. T-cells in regenerating feather of Smyth line chickens with vitiligo. Clin Immunol Immunopathol 1995; 76: 120–126. 148 Austin L, Boissy R, Jacobson B, et al. The detection of melanocytes auto-antibodies in the Smyth line chickens model for vitiligo. Clin Immunol Dermopathol 1992; 64: 12–120. Citing Literature Volume45, Issue5May 2006Pages 583-590 ReferencesRelatedInformation
Referência(s)